Assessment of Lifetime Risk for Cardiovascular Disease: Time to Move Forward
- PMID: 38963102
- PMCID: PMC11440323
- DOI: 10.2174/011573403X311031240703080650
Assessment of Lifetime Risk for Cardiovascular Disease: Time to Move Forward
Abstract
Over the past decades, there has been a notable increase in the risk of Cardiovascular Disease (CVD), even among younger individuals. Policymakers and the health community have revised CVD prevention programs to include younger people in order to take these new circumstances into account. A variety of CVD risk assessment tools have been developed in the past years with the aim of identifying potential CVD candidates at the population level; however, they can hardly discriminate against younger individuals at high risk of CVD.Therefore, in addition to the traditional 10-year CVD risk assessment, lifetime CVD risk assessment has recently been recommended by the American Heart Association/American College of Cardiology and the European Society of Cardiology prevention guidelines, particularly for young individuals. Methodologically, the benefits of these lifetime prediction models are the incorporation of left truncation observed in survival curves and the risk of competing events which are not considered equivalent in the common survival analysis. Thus, lifetime risk data are easily understandable and can be utilized as a risk communication tool for Public Health surveillance. However, given the peculiarities behind these estimates, structural harmonization should be conducted in order to create a sex-, race-specific tool that is sensitive to accurately identifying individuals who are at high risk of CVD. In this review manuscript, we present the most commonly used lifetime CVD risk tools, elucidate several methodological and critical points, their limitations, and the rationale behind their integration into everyday clinical practice.
Keywords: Lifetime risk; cardiovascular disease; epidemiology; harmonization; hypercholesterolemia.; risk assessment.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Conflict of interest statement
The authors declare no conflict of interest, financial or otherwise.
Similar articles
-
Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.Eur J Prev Cardiol. 2024 Oct 10;31(14):1690-1699. doi: 10.1093/eurjpc/zwae174. Eur J Prev Cardiol. 2024. PMID: 38752762 Free PMC article.
-
Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP).Eur Heart J Acute Cardiovasc Care. 2020 Aug;9(5):522-532. doi: 10.1177/2048872619858285. Epub 2019 Jun 25. Eur Heart J Acute Cardiovasc Care. 2020. PMID: 31303009 Review.
-
External validation of the QLifetime cardiovascular risk prediction tool: population cohort study.BMC Cardiovasc Disord. 2023 Apr 15;23(1):194. doi: 10.1186/s12872-023-03209-8. BMC Cardiovasc Disord. 2023. PMID: 37061672 Free PMC article.
-
Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines.Circ Cardiovasc Qual Outcomes. 2021 Sep;14(9):e007183. doi: 10.1161/CIRCOUTCOMES.120.007183. Epub 2021 Sep 21. Circ Cardiovasc Qual Outcomes. 2021. PMID: 34546786
-
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Drug Des Devel Ther. 2011;5:325-80. doi: 10.2147/DDDT.S14934. Epub 2011 Jun 13. Drug Des Devel Ther. 2011. PMID: 21792295 Free PMC article. Review.
References
-
- Sun J., Qiao Y., Zhao M., Magnussen C.G., Xi B. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15–39 years in 204 countries/territories, 1990–2019: a systematic analysis of Global Burden of Disease Study 2019. BMC Med. 2023;21(1):222. doi: 10.1186/s12916-023-02925-4. - DOI - PMC - PubMed
-
- Grundy S.M., Stone N.J., Bailey A.L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–e1143. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous